Entrada Therapeutics is focused on developing a new class of intracellular therapeutics aimed at treating devastating diseases. Central to their approach is the proprietary EEV™ (Endosomal Escape Vehicle) Platform, which is designed to effectively deliver therapeutic agents to previously inaccessible and undruggable targets within cells. This platform is characterized by its versatility and modularity, allowing for broad applications across various therapeutic areas. Entrada is actively advancing its pipeline, which includes potential treatments that range from discovery to clinical stages for multiple serious conditions.

The company emphasizes the importance of scientific transparency and ethical standards in its research and publications. Their commitment to publishing results in a timely and accurate manner aligns with recognized industry guidelines, ensuring that their findings contribute to the broader scientific community. Notable research includes studies on cell-penetrating peptides and their mechanisms for enhancing the delivery of therapeutic oligonucleotides, which are crucial for addressing neuromuscular disorders. Through these innovative technologies, Entrada Therapeutics aims to transform patient care and improve outcomes for those affected by challenging diseases.

United States

Entrada Therapeutics is a biotechnology company dedicated totreatingdevastating diseases through the intracellular delivery of biologics

Entrada Therapeutics

Company Details